A2
Agmatine sulfate
- Product declaration
- Agmatine Sulfate: 1500 mg
- Selected studied range
- No dose range selected
- Protocol and duration
- Not recorded in the selected comparison
- Studied context
- Human data is comparatively sparse. A randomized double-blind placebo-controlled trial studied oral agmatine sulfate (1,335-3,560 mg/day for up to 3 weeks) for lumbar disc-associated radiculopathy (a clinical/pain context, not sports performance). A 2019 Scientific Reports paper examined safety and neurochemical profiles of acute and sub-chronic oral agmatine sulfate treatment.
- Limitations
- Sports-performance-specific human efficacy data for agmatine sulfate (e.g., a dedicated ISSN position stand) was not located in this research pass. Evidence located centers on safety/tolerability and non-sports clinical contexts rather than an authoritative performance-outcome verdict. Long-term safety in larger populations remains an open gap per the safety literature reviewed.
Selected evidence: Safety and neurochemical profiles of oral agmatine sulfate, 2019 · Open source
